Study S002399

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (EMBOLD-Asia)

ClinicalTrials.gov record

Registration

Registration: NCT07775404
Acronym: Elecoglipron
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 351
Start: 2026-08-21
Primary completion: 2028-04-06
Lead sponsor: AstraZeneca
Conditions: Obesity; Overweight
Interventions: DRUG:Elecoglipron; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Percent change from baseline to Week 52 in body weight [Week 52]
Participants achieving at least 5% body weight loss at Week 52 [Week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.